Heart Failure With Preserved Ejection Fraction
Conditions
Keywords
Epicardial Adipose tissue, Cardiac Function
Brief summary
Heart failure with preserved ejection fraction (HFpEF) refers to a group of symptoms and signs of heart failure, normal or near-normal left ventricular systolic function (EF\>50%), and ventricular muscle diastolic dysfunction and A clinical syndrome characterized by decreased compliance and increased stiffness. The pathogenesis of HFpEF is related to impaired lipid metabolism and inflammation. Epicardial adipose tissue (Epicardial Adipose tissue, EAT) is a kind of visceral adipose tissue. Related studies have shown that extracardiac Membrane fat is related to inflammation markers, cardiometabolic risk and cardiovascular disease.However, there is still no research investigating the the relationship between epicardial fat thickness and Cardiac Function in HFpEF patients.
Detailed description
Heart failure with preserved ejection fraction (HFpEF) refers to a group of symptoms and signs of heart failure, normal or near-normal left ventricular systolic function (EF\>50%), and ventricular muscle diastolic dysfunction and A clinical syndrome characterized by decreased compliance and increased stiffness. The pathogenesis of HFpEF is related to impaired lipid metabolism and inflammation. Epicardial adipose tissue (Epicardial Adipose tissue, EAT) is a kind of visceral adipose tissue, which is composed of adipose tissue deposited between the myocardium and the visceral layer of the pericardium. It is closely adjacent to the coronary arteries and myocardium. Related studies have shown that extracardiac Membrane fat is related to inflammation markers, cardiometabolic risk and cardiovascular disease.However, there is still no research investigating the the relationship between epicardial fat thickness and Cardiac Function in HFpEF patients. This study intends to observe the relationship between epicardial fat thickness and left and right functions in patients with HFpEF, and evaluate whether epicardial fat thickness can be used as an indicator of left and right dysfunction.
Interventions
None listed
Sponsors
Dongying Zhang
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult aged \>=18years old; * Diagnosed with HFpEF. Diagnostic criteria including: 1. left ventricular ejection fraction ≥50%； 2. with the symptoms and/or signs of heart failure； 3. BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL； 4. at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction
Exclusion criteria
* LVEF less than 45% at any time; * Severe liver failure; * Primary pulmonary hypertension; * Age \<18 years old.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Epicardial Fat Tissue | On admission | Epicardial Fat Tissue by cardiac color Doppler ultrasound |
| Cardiac Function | On admission | Left ventricular diastolic function and right ventricular systolic function by cardiac color Doppler ultrasound |
| Composite Endpoint of Worsening Heart Failure Event and Cardiovascular Death | From date of discharge until the date of first worsening HF event or date of death, whichever came first, assessed up to 5 years | Composite Endpoint of Worsening Heart Failure Event and Cardiovascular Death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Worsening HF Event | From date of discharge until the date of first worsening HF event or date of death, whichever came first, assessed up to 5 years | Worsening Heart Failure Event |
| CV Death | From date of discharge until the date of death, whichever came first, assessed up to 10 years | Cardiovascular Death |
| All-cause Death | From date of discharge until the date of death, whichever came first, assessed up to 10 years | Death from any causes |
Countries
China
Outcome results
None listed